CD19-CAR-T Cells Bearing a KIR/PD-1-Based Inhibitory CAR Eradicate CD19+HLA-C1− Malignant B Cells While Sparing CD19+HLA-C1+ Healthy B Cells
Lei Tao(East China Normal University), Wenzheng Jiang(East China Normal University), Congyi Niu(Suzhou Institute of Systems Medicine), Cong He(East China Normal University), Guixia Zhao(East China Normal University), Iqra Ajmal(East China Normal University), Yaoxin Gao(First Affiliated Hospital of Zhengzhou University), Li Zhang(Xinjiang Medical University), Jie Yao(East China Normal University), Mingyao Liu(East China Normal University), Ying Zhou(Tongji University), Muhammad Asad Farooq(East China Normal University)
Cited by 36
Related Papers
Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma
|Nature|2019|982
Dual base editor catalyzes both cytosine and adenine base conversions in human cells
|Nature Biotechnology|2020|294
Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis
|Cell|2024|272
Gambogic Acid Inhibits Angiogenesis and Prostate Tumor Growth by Suppressing Vascular Endothelial Growth Factor Receptor 2 Signaling
|Cancer Research|2008|237
Engineering a precise adenine base editor with minimal bystander editing
|Nature Chemical Biology|2022|183